HCC-话题@MedSci

#HCC#

114篇内容 | 4667人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259530, encodeId=cc22125953074, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, objectType=article, longId=211682, objectId=d50921168225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50921168225, replyNumber=0, likeNumber=79, createdTime=2021-05-24, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50921168225, moduleTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50921168225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259529, encodeId=659812595297f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=58, createdTime=2021-05-22, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259528, encodeId=f511125952812, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=70, createdTime=2021-05-21, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259527, encodeId=df75125952ef4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=69, createdTime=2021-05-20, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259526, encodeId=031b125952633, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, objectType=article, longId=210866, objectId=2f0121086637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0121086637, replyNumber=0, likeNumber=93, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0121086637, moduleTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0121086637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259525, encodeId=bf98125952536, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：放射组学在预测早期HCC复发中的应用, objectType=article, longId=210836, objectId=ae51210836aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae51210836aa, replyNumber=0, likeNumber=79, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae51210836aa, moduleTitle=Radiology：放射组学在预测早期HCC复发中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae51210836aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259524, encodeId=6a96125952439, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, objectType=article, longId=210789, objectId=6ad8210e89ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad8210e89ae, replyNumber=0, likeNumber=100, createdTime=2021-05-05, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad8210e89ae, moduleTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad8210e89ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259523, encodeId=b8e31259523ef, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, objectType=article, longId=210100, objectId=8451210100cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8451210100cd, replyNumber=0, likeNumber=65, createdTime=2021-04-19, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8451210100cd, moduleTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8451210100cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259522, encodeId=59b71259522ae, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, objectType=article, longId=205226, objectId=9130205226b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9130205226b7, replyNumber=0, likeNumber=69, createdTime=2021-01-04, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9130205226b7, moduleTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9130205226b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259521, encodeId=4331125952148, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制, objectType=article, longId=202951, objectId=dc73202951dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc73202951dc, replyNumber=0, likeNumber=0, createdTime=2020-11-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73202951dc, moduleTitle=Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73202951dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259520, encodeId=d751125952017, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢, objectType=article, longId=197268, objectId=1caa19e26835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1caa19e26835, replyNumber=0, likeNumber=82, createdTime=2020-07-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1caa19e26835, moduleTitle=Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1caa19e26835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259519, encodeId=e28312595196d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）, objectType=article, longId=195882, objectId=693819588287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693819588287, replyNumber=0, likeNumber=60, createdTime=2020-06-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693819588287, moduleTitle=NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693819588287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259518, encodeId=293912595183d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ASCO肝细胞癌（HCC）相关口头报告速览, objectType=article, longId=194518, objectId=32961945180c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32961945180c, replyNumber=0, likeNumber=48, createdTime=2020-05-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32961945180c, moduleTitle=ASCO肝细胞癌（HCC）相关口头报告速览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32961945180c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259517, encodeId=daba125951e97, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, objectType=article, longId=193347, objectId=3a3319334ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a3319334ea1, replyNumber=0, likeNumber=97, createdTime=2020-05-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a3319334ea1, moduleTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a3319334ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259516, encodeId=a58f125951685, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用, objectType=article, longId=183620, objectId=bf1d18362012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1d18362012, replyNumber=0, likeNumber=61, createdTime=2019-11-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1d18362012, moduleTitle=Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1d18362012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259515, encodeId=4b5c1259515ba, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS, objectType=article, longId=175184, objectId=78551e518428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78551e518428, replyNumber=0, likeNumber=67, createdTime=2019-07-12, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78551e518428, moduleTitle=JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78551e518428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259514, encodeId=c8ce1259514ff, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, objectType=article, longId=174829, objectId=8b6f1e482903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6f1e482903, replyNumber=0, likeNumber=62, createdTime=2019-07-06, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6f1e482903, moduleTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6f1e482903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259513, encodeId=5efb125951322, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台, objectType=article, longId=168219, objectId=67eb168219fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67eb168219fd, replyNumber=0, likeNumber=40, createdTime=2019-06-14, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67eb168219fd, moduleTitle=【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67eb168219fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259512, encodeId=cb1512595128c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, objectType=article, longId=161437, objectId=0fed16143ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fed16143ef7, replyNumber=0, likeNumber=66, createdTime=2019-03-02, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fed16143ef7, moduleTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fed16143ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259511, encodeId=2ba812595116a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异, objectType=article, longId=156075, objectId=86e41560e596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86e41560e596, replyNumber=0, likeNumber=60, createdTime=2018-12-19, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86e41560e596, moduleTitle=J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86e41560e596)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果

2021-05-24

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-05-22

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-21

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-05-20

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：放射组学在预测早期HCC复发中的应用

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现

2021-05-05

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要

2021-04-19

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”

2021-01-04

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制

2020-11-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢

2020-07-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）

2020-06-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ASCO肝细胞癌（HCC）相关口头报告速览

2020-05-23

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药

2020-05-03

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用

2019-11-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS

2019-07-12

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位

2019-07-06

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台

2019-06-14

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药

2019-03-02

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异

2018-12-19

科室
- - 订阅+
  - 更多科室
工具
服务